23 December 2021 in Journal of International Medical Research
Aim: To assess the effects of incretin-based therapies on β-cell function in patients with type 1 diabetes mellitus (T1DM). Methods: We searched the PubMed, Cochrane Library, Embase, and Web of Knowledge databases for eligible randomized clinical trials published up to July 2021. The inclusion criteria were patients with T1DM or latent autoimmune diabetes in adults, patients treated with dipeptidyl peptidase-4 inhibitors or glucagon like peptide-1 receptor agonists, and outcomes included one of the following: fasting plasma glucose, fasting C-peptide, postprandial C-peptide, C-peptide area under the curve (AUC), homeostasis model assessment for β cell function, and insulin resistance. The effects were analyzed using a random effect model with STATA 11.0. Results: Eight trials including 427 participants were included in the final analysis. A pooled analysis found no significant difference in fasting plasma glucose, fasting C-peptide, postprandial C-peptide, or C-peptide AUC between patients treated with incretin-based therapies and placebo. The two trials that reported changes in 2-hour postprandial C-peptide and two of the four trials that reported changes in C-peptide AUC reported increases after incretin-based therapies. Conclusion: This meta-analysis showed that incretin-based therapies did not preserve β-cell function in patients with T1DM.
9 October 2026 in Metabolic Syndrome and Related Disorders
Background: The triglyceride-glucose (TyG) index has been associated with atherosclerotic cardiovascular disease (ASCVD) risk. However, the associations of TyG-related indices combined with obesity measures, including body mass index, waist circumference (WC), waist-to-height ratio, and body roundness index, with 10-year ASCVD risk across different populations remain unclear. Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS; n = 8224) and the National Health and Nutrition Examination Survey (NHANES; n = 13,527) were analyzed. Weighted multivariable logistic regression, restricted cubic spline (RCS) analyses, and subgroup analyses were performed to evaluate the associations between TyG-related indices and 10-year ASCVD risk. Results: TyG and TyG-related indices were significantly associated with higher 10-year ASCVD risk in both cohorts. Nonlinear associations were observed between several TyG-related indices and ASCVD risk. Compared with the U.S. population, obesity-related TyG composite indices showed relatively stronger associations with ASCVD risk among Chinese adults. Subgroup analyses demonstrated more pronounced associations among females in the CHARLS cohort, whereas in NHANES, significant sex differences were observed only for the TyG index. Among the evaluated indices, TyG–WC showed relatively stronger associations with ASCVD risk across both datasets. Conclusion: TyG-related indices were significantly associated with 10-year ASCVD risk across Chinese and U.S. populations, although the strength of these associations varied between populations. TyG–WC may provide additional value for ASCVD risk assessment. Further longitudinal studies are warranted to validate these findings and clarify the underlying mechanisms.